Transthyretin amyloidosis (ATTR) is caused by deposition of either wild-type (ATTRwt) or variant (ATTRm) transthyretin. ATTRwt presents with restrictive cardiomyopathy, while ATTRm displays a range of organ involvement. This retrospective analysis includes all patients referred to a single UK center in the last 25 years for clinical and laboratory assessment of known or suspected amyloidosis who underwent TTR gene sequencing. A total of 4459 patients were included in this study; 37% had final diagnosis of ATTR amyloidosis; 27% light chain amyloidosis; 0.7% other types of amyloidosis; 21.3% had no amyloid and 14% had no data. TTR variants were found in 770 (17%) cases; the most prevalent were p.V142I, p.T80A, and p.V50M identified in 42, 25, and 16%, respectively. The median age at referral in each group was: 76 (range 47-93), 66 (40-81), and 45 years (21-86), respectively. Overall 42 rare or novel variants were identified. Forty-two percent patients with ATTRm died at a median age of 73 years (33-89) with a median survival from diagnosis of 50 months. ATTRwt was the final diagnosis in 20% of patients undergoing genetic testing. Our findings of TTR variants in 17% of screened patients highlight the need for routine genetic testing in the evaluation of suspected ATTR amyloidosis.
INTRODUCTION
Transthyretin amyloidosis (ATTR) is caused by a deposition of fibrils, which may be derived from either wild-type (ATTRwt) or variant transthyretin (ATTRm). Transthyretin (TTR) is synthesized primarily in the liver, but also in the choroid plexus and retina. In its native state, TTR is a homotetramer made of four monomers rich in -sheet structure. Mutations in the TTR gene, strong biomechanical forces, and proteolytic cleavage have all been reported to play a crucial role in destabilizing the TTR tetramer and release of a highly amyloidogenic 49-127 truncated protomer (Kelly, 2000; Marcoux et al., 2015) .
The TTR gene (MIM# 176300) (NCBI Reference Sequence NM_000371.3) is located on chromosome 18 and is known to be highly polymorphic with more than 140 variants of which 130 are amyloidogenic (Rowczenio et al., 2014) . With the exception of a valine residue deletion at position 142 and the recently reported six nucleotides duplication (c.212_217dupAGTCTG ) in exon 3 of the TTR gene (Klimtchuk et al., 2018) , all variants are nucleotide substitutions.
The possibly most common presenting phenotype associated with ATTRm (MIM# 105210) amyloidosis is familial amyloid polyneuropathy (FAP), in which amyloid deposition can affect any or all of major viscera including peripheral nerves, heart, gastrointestinal tract, vitreous, lungs, and carpal ligament. Unlike FAP, in familial amyloid cardiomyopathy (FAC) ATTR amyloid accumulates predominantly in the heart causing progressive cardiomyopathy mainly characterized by diastolic dysfunction.
The earliest reported and most widely studied worldwide TTR variant is p.V50M. This was first described in 1952 in Portuguese kindreds with familial amyloid polyneuropathy (FAP) (Andrade, 1952) . Subsequently large patient clusters in Portugal (Saraiva, Birken, Costa, & Goodman, 1984) , Japan (Araki, Kurihara, Tawara, & Kuribayashi, 1980) , and Sweden (Holmgren et al., 1994; Olsson, Jonasson, Cederquist, & Suhr, 2014; Sousa, Andersson, Drugge, Holmgren, & Sandgren, 1993) have been reported, with a considerable phenotypic variation in the age of onset, rate of disease progression, involvement of different organ systems, and penetrance. The possibly most prevalent TTR variant is p.V142I, which has been found at high frequency in patients of West African descent (Jacobson et al., 2016) . The clinical syndrome associated with this mutation is a late-onset restrictive cardiomyopathy and progressive heart failure with life expectancy up to 5 years from diagnosis (Ando et al., 2013; Connors et al., 2009 ). The estimated allele frequency among African-Americans for p.V142I is 3.9% and cohort studies suggest allele carriers were at greater risk of heart failure even in the absence of overt amyloid deposits (Quarta et al., 2015) .
The phenotype of p.V142I ATTR amyloidosis clinically resembles that of the ATTRwt amyloidosis, as the late-onset restrictive cardiomyopathy is the cardinal feature in both. The latter however is caused by the deposition of wild-type transthyretin and predominantly affects elderly Caucasian males. The disease is most likely underdiagnosed, as an autopsy study revealed ATTRwt amyloid deposits were present in 25% of people over the age of 85 years (Tanskanen et al., 2008) , but the prevalence of ATTRwt amyloid deposits leading to clinical syndrome of ATTRwt cardiac amyloidosis has not yet been elucidated.
Interestingly, TTR tetramer comprising the non-pathogenic p.T139M TTR variant was found to be highly stable, and to play an inhibitory role in the ATTR fibrils formation (Marcoux et al., 2015) .
In Portuguese families who were found compound heterozygotes for the p.T139M and p.V50M; the p.T139M attenuated the effects of the pathogenic p.V50M substitution, reducing the severity of the symptoms (Sebastiao, Lamzin, Saraiva, & Damas, 2001) .
The UK National Amyloidosis Centre (NAC) is a national and international referral center, which includes a long standing collaboration with Cyprus and it has been involved in diagnosis and management advisory service for patients with amyloidosis since 1990.
In this retrospective review, we report the genetic testing results for patients with known or suspected amyloidosis who underwent TTR gene sequencing as part of their routine workup over the last 25 years.
SUBJECT AND METHODS
This retrospective analysis included 4459 patients referred to a single UK specialist center between 1992 and 2017 for assessment of known or suspected amyloidosis who underwent TTR gene sequencing as part of their routine workup. Of these 3946 (88.5%) had been assessed at the NAC and blood or DNA from the remaining cases was sent to NAC for a genetic review. The patients assessed at the NAC underwent additional clinical and laboratory investigations including histology with immunohistochemistry (Gilbertson, Hunt, & Hawkins, 2012) , laser micro dissection (LMD) of the amyloid deposits followed (Hawkins et al., 1993; Hutt et al., 2014) , and measurements of cardiac biomarker NT-pro BNP (Wechalekar et al., 2011) . The presence of a monoclonal protein was sought by serum free light chain (AL) assay, conventional electrophoresis, and immunofixation of serum or urine.
Patient survival from the time of diagnosis was analyzed by Kaplan-Meier analysis using GraphPad Prism v5.03 software.
Informed consent was provided by all subjects included in this study, and the ethical approval for the study was obtained from Royal Free Hospital and University College Medical School Research Ethics Committee (REC reference number 06/Q0501/42).
DNA AMPLIFICATION AND DIRECT SEQUENCE ANALYSIS OF TTR GENE
Genomic DNA in all patients was extracted from whole blood treated with EDTA (Talmud et al., 1991) . The coding regions of the TTR gene were amplified by PCR assay and analyzed by automated sequencing. Amplification was carried out with Ready-To-Go tubes (Amersham Pharmacia Biotech, Piscataway, NJ) with the use of primers, solutions, and cycling conditions that have been described previously (Booth, Tan, Hawkins, Pepys, & Frustaci, 1995) . The PCR products were purified with a QIAquick PCR purification kit (Qiagen, Velno, the Netherlands) according to the manufacturer's protocol and sequenced with the Big Dye Terminator v 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) following the procedures recommended by manufacturers.
The sequence of the TTR gene was analyzed on the ABI 3130xl Genetic Analyser, using Sequencing Analysis Software version 5.4.
RESULTS
Of the 4459 patients in whom the TTR gene was sequenced 37% had the final diagnoses of ATTR amyloidosis; 27% light chain amyloidosis; 0.7% other types of amyloidosis; 21.3% had no evidence of amyloid deposition and in 14%, we have no data. Forty-five different TTR variants were identified in 770 (17%) of the 4459 individuals that underwent TTR gene testing between 1992 and 2017; 695 (92%) were assessed at the NAC. The list of TTR variants and number of cases associated with each variant are shown in Figure 1A . The most prevalent were: p.V142I identified in 323 subjects (42%, 72% of whom were male), p.T80A in 193 (25%, 66% of whom were male), and p.V50M in 121 (16%, 75% of whom were male). The demographics for these three variants are shown in Table 1 . Nearly 50% of cohort with p.V142I had Afro-Caribbean ancestry, the remaining originated from different regions of Africa, mostly from the West. The TTR p.T80A was identified largely in patients of Irish ancestry, but 16% of the cohort were Scottish and p.V50M was found in a heterogeneous group of patients: 55% were of Greek-Cypriot/Greek ancestry, 29% were British, and the remaining cases were from Portugal (5%), Sweden (4%), Ireland (3%), and the Middle East (4%). The median age at referral in each group was: 76 years (range 47-93), 66 years (40-81), and 45 years (21-86), Of note, in the same period of time, we have seen a dramatic increase in diagnosis of ATTRwt with 929 new cases to date ( Figure 3A) . This cohort accounts for 10% of all amyloid diagnosis at our center and for 59% of ATTR patients ( Figure 3B and C) . As expected, 94% of our ATTRwt patients were Caucasian males, with a median age at disease diagnosis of 78 years (range 51-95). Of them, 305 (33%) have died; the median age at death was 81 years (range 63-96) with a median survival from diagnosis of 60 months (range 1-249).
DISCUSSION
Hereditary ATTR amyloidosis is the commonest form of familial amyloidosis. TTR gene variants have been reported to be associated with variable amyloid organ involvement, but the neurological and cardiac symptoms, often leading to progressive and disabling peripheral and autonomic neuropathy or severe cardiomyopathy are the most commonly reported clinical features (Connors, Lim, Prokaeva, Roskens, & Costello, 2003; Rapezzi et al., 2013) . Here, we describe the outcome of TTR gene analysis performed in our center since it was implemented into our routine diagnostic workup for patients with suspected ATTR amyloidosis. Our study has the largest cohort of patients with suspected systemic amyloidosis to have undergone TTR gene sequencing. ATTRm was identified in 17% of cases, while ATTRwt accounted for 20% of diagnoses. The TTR p.V142I variant was the commonest finding and nearly 50% of these had Afro-Caribbean ancestry, our ethnic distribution is in line with the demographics of the South East of the United Kingdom. It is important to highlight that presence of a mutation cannot be relied to confirm the amyloid type as p.V142I was incidentally found in five patients (all of Afro-Caribbean ancestry) who were definitively diagnosed with AL amyloidosis, four of five cases presented with isolated cardiac amyloidosis.
The second most common TTR variant (25%) was p.T80A found predominantly in kindreds of Irish ancestry, consistent with the known founder effect (Reilly, Staunton, & Harding, 1995) in whom the median age at diagnosis was 66 years and cardiac symptoms were the principal manifestations, but 80% of cases had some degree of peripheral and autonomic neuropathy. Consistent with a previous report (Sattianayagam et al., 2012) , only 35% of cases had a positive family history of amyloidosis. The TTR p.V50M was found in 16% of all ATTRm cases. There was a significant difference between the age at onset for patients of Greek-Cypriot/Greek ancestry when compared to British subjects (median 35 years (range 21-70) vs. 68 years (42-86) P < 0.0001, and also marked difference in the clinical features, with the former suffering predominantly with neurological symptoms while the later had cardiac dominated disease. Forty-two other rare variants were found, of which five were novel. The anatomical location of ATTR fibril deposition associated with the novel mutations was consistent with other known variants in that the nerves and the heart were primarily affected.
In the three best recognized TTR substitutions (p.V142I, p.T80A, and p.V50M), there was evidence of a gene dosage effect with homozygous patients presenting at a younger age than heterozygotes.
Survival from diagnosis varied, depending on the type of TTR variant. Patients with the p.V50M had over 10 years survival, which was most likely due to successful liver transplantation (LT) and younger age at presentation. LT has been the only curative treatment in this disorder and is considered to be particularly beneficial for earlyonset TTR p.V50M patients, while those with other variants were reported to have paradoxical acceleration of transthyretin amyloid deposition in the heart following LT (Stangou & Hawkins, 2004; Stangou et al., 2005) . The recent advances in treatment for ATTR amyloidosis including drugs blocking translation of the TTR protein (Adams et al., 2016; Adams, Cauquil, & Labeyrie, 2017; Maurer et al., 2018) ATTR accounts for a steadily increasing proportion of newly diagnosed amyloidosis. This probably reflects advances in imaging modalities rather than a true change in disease demographics.
Our cohort reflects a mixed ethnicity population with a relatively low frequency of TTR p.V50M compared to reports from other countries (Araki et al., 1980; Lobato, 2003; Suhr et al., 2003) . We identified 45 different TTR variants, which can be found in the online registry for hereditary amyloidosis at www.amyloidosismutations.com. The majority were associated with a mixed cardiac and neurological phenotype;
10 were found to cause isolated cardiac amyloidosis and nine had been associated with isolated neurological symptoms. Early disease onset (median 43 years (range 32-46)) and poor survival was seen with the rare TTR variants: p.L32P, p.F53L, p.G67E, and p.V91A, which presented as aggressive, rapidly progressing, and disabling peripheral and autonomic neuropathy. However, the incidental finding of TTR variants in some cases with AL amyloidosis shows the importance of interpreting genetics in clinical context.
Our findings of ATTRm in 17% of screened patients and the late presentation of TTRm amyloid, with over 70% aged 60 and 80 years old at diagnosis, highlights the importance of genetic testing in routine clinical evaluation of patients with suspected systemic amyloidosis.
Previously TTR gene screening was used in the diagnostic workup-to avoid misdiagnosis of AL amyloidosis, which can be treated with chemotherapy, to provide information for family members, and to allow highly selected patients to be considered for liver transplantation. With advances in therapy and the promising results from silencing RNA and antisense oligonucleotides clinical trials we are on the threshold of a new era in the treatment of TTR amyloidosis with the imminent licensing of targeted gene silencing agents and thus an even greater importance for establishing the exact nature of the precursor protein (Adams et al., 2017; Adams et al., 2016; Maurer et al., 2018) .
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